Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q1 FY20 results · Apr–Jun 2019
Panacea Biotec reported revenue from operations of ₹125.78 crore and net loss of ₹28.27 crore for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 125.78 | — | — | — | — |
| Other income | 5.03 | — | — | — | — |
| Total income | 130.81 | — | — | — | — |
| Profit before share of associates & JVs and tax | (23.75) | — | — | — | — |
| Share of profit/(loss) of associates & JVs | 0.07 | — | — | ||
| Net profit for the period | (28.27) | — | — | — | — |
| EPS, basic (₹) | (4.62) | — | — | — | — |
| Net margin (%) | -22.5 | — | — |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 24.82 | 95.11 | −73.9% | 29.26 | −15.2% |
| Other income | 1.14 | 3.33 | −65.8% | 1.13 | +0.9% |
| Total income | 25.96 | 98.44 | −73.6% | 30.39 | −14.6% |
| Profit before tax | (18.81) | (34.17) | Loss narrowed | 218.69 | Turned loss |
| Net profit for the period | (29.21) | (36.83) | Loss narrowed | 183.90 | Turned loss |
| EPS, basic (₹) | (4.77) | (6.01) | Loss narrowed | 30.02 | Turned loss |
| Net margin (%) | -117.7 | -38.7 | 628.5 |
Consolidated
- Filed with BSE
- 14 Aug 2019, 16:04 IST
- Board meeting
- 12 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Aug 2019, 16:04 IST
- Board meeting
- 12 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE